CORMEDIX INC. - COMMON STOCK
10.81
08-January-25 16:45:00
15 minutes delayed
Stocks
+0.51
+4.95%
Today's range
10.11 - 11.00
ISIN
N/A
Source
NASDAQ
-
28 Jun 2023 22:57:02 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
28 Jun 2023 16:07:53 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
21 Jun 2023 08:30:00 By Nasdaq GlobeNewswire
-
15 Jun 2023 08:30:00 By Nasdaq GlobeNewswire
-
Cormedix Inc. To Present At The Jefferies Healthcare Conference
30 May 2023 08:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
16 May 2023 07:00:01 By Nasdaq GlobeNewswire
-
CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 2023 16:05:01 By Nasdaq GlobeNewswire
-
08 May 2023 08:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
03 May 2023 08:30:00 By Nasdaq GlobeNewswire
-
01 May 2023 08:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
26 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
-
Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors
17 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
-
30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire
-
21 Mar 2023 08:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces Regulatory and Manufacturing Updates
02 Mar 2023 16:05:01 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
17 Jan 2023 08:30:00 By Nasdaq GlobeNewswire
-
06 Dec 2022 08:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 2022 07:30:00 By Nasdaq GlobeNewswire
-
CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
07 Nov 2022 08:30:00 By Nasdaq GlobeNewswire
-
02 Nov 2022 08:30:00 By Nasdaq GlobeNewswire